Supplemental Figure 1



Supplemental Figure 2



Supplemental Figure 3





Supplementary Table 1: Baseline clinical characteristics of enrolled HD and excluded patients.

	Enrolled HD (n=69)	Excluded HD (n=138)		
		PET2 positive (n=35)	PET3 or PET4 positive (n=18)	Missing PET4 (n=85)
Age	39 ± 13 (range 19-58)	34 ± 9 (range 17-64)	36 ± 8 (range 23-48)	52 ± 21 (range 27-66)
Male Sex	37/69 (53%)	24/35 (68%)	12/18 (66%)	45/85 (52%)
Weight (Kg)	67.1 ± 12	64.6 ± 8	72.8 ± 14	75.2 ± 9
Gycemia at FDG injection (mg/dl)	79 ± 7	71 ± 10	67 ± 19	82 ± 15
Cardiovascular Risk Profile				
Hypertension	6/69 (8%)	5/35 (14%)	2/18 (11%)	29/85 (34%)
Tobacco Use	19/69 (27%)	10/35 (28%)	4/18 (22%)	14/85 (16%)
Total Cholesterol	183.7 ± 30	173.4 ± 19	201.4 ± 62	196.8 ± 54
LDL	114.5 ± 32	109 ± 15	107 ± 47	132.1 ± 52
Triglycerides	121.3 ± 49	115.9 ± 55	140 ± 76	191.6 ± 103
Creatinine	0.8 ± 0.1	1.1 ± 0.4	0.9 ± 0.2	1.1 ± 0.4
Family hystory of CAD	7/69 (10%)	7/35 (20%)	2/18 (11%)	14/85 (16%)
Time intervals between PET studies				
PET1 - PET2 (days)	73.7 ± 21	69.9 ± 32	79.3 ± 15	76.1 ± 22
PET2 - PET3 (days)	148 ± 70	117.5 ± 101	156.1 ± 91	141.2 ± 71
PET3 - PET4 (days)	195 ± 92	116.5 ± 143	122.9 ± 134	-
Baseline Ann-Arbor Staging				
I Stage	7/69 (10%)	1/35 (2%)	0/18 (0%)	21/85 (24%)
II Stage	42/69 (60%)	12/35 (34%)	9/18 (50%)	31/85 (36%)
III Stage	8/69 (12%)	12/35 (34%)	7/18 (38%)	19/85 (22%)
IV Stage	12/69 (17%)	10/35 (28%)	2/18 (11%)	14/85 (16%)
B symptoms	10/69 (14%)	4/35 (11%)	6/18 (33%)	33/85 (38%)